Skip to main content

Table 1 Clinicopathological parameters for patients with early TNBC

From: Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Characteristics

All patients (n = 29)

Responders (RCB-0/I, n = 21)

Non-responders (RCB-II/III, n = 8)

p value*

Age

56.3 (± 12.8)

56.7 (± 12)

55.4 (± 15)

0.83

Menopausal status

   

0.43

 Non-menopausal

11 (38%)

7 (33%)

4 (50%)

 

 Menopausal

18 (62%)

14 (67%)

4 (50%)

 

Histological type

   

1

 IDC

26 (90%)

19 (90%)

7 (88%)

 

 ILC

3 (10%)

2 (10%)

1 (12%)

 

 Tumor size (larger diameter—in mm)

36 ± 24

28 ± 15

56 ± 32

0.04

Unifocal

   

0.20

 Yes

18 (62%)

15 (71%)

3 (38%)

 

 No

11 (38%)

6 (29%)

5 (62%)

 

Grade

   

1

 I

0

0

0

 

 II

3 (10%)

2 (10%)

1 (12%)

 

 III

26 (90%)

19 (90%)

7 (88%)

 

Ki67

   

-

  < 15%

0

0

0

 

  ≥ 15%

29 (100%)

21 (100%)

8 (100%)

 

Nodal invasion at diagnosis

   

0.68

 Yes

12 (41%)

8 (38%)

4 (50%)

 

 No

17 (59%)

13 (62%)

4 (50%)

 

Type of NAC

   

0.07

 EC-T

27 (93%)

21 (100%)

6 (75%)

 

 EC-T-C

2 (7%)

0

2 (25%)

 

Type of breast surgery

   

0.01

 BCS

11 (38%)

11 (52%)

0

 

 Mastectomy

18 (62%)

10 (48%)

8 (100%)

 

Type of axillary surgery

   

0.02

 SLNB

11 (38%)

11 (52%)

0

 

 ALND

18 (62%)

10 (48%)

8 (100%)

 

Adjuvant radiotherapy

   

0.67

 Yes

20 (69%)

15 (71%)

5 (63%)

 

 No

9 (31%)

6 (29%)

3 (37%)

 
  1. Responders and non-responders correspond to patients with RCB 0/I or II/III, respectively. ALND axillary lymph node dissection, BCS breast-conserving surgery, EC-T epirubicin/cyclophosphamide-taxane, EC-T-C epirubicin/cyclophosphamide-taxane-carboplatin, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, SLNB sentinel lymph node biopsy.
  2. *Fisher’s exact test was used for categorical variables and t test for continuous ones